Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 212

1.

Clinical experiences with cannabinoids in spasticity management in multiple sclerosis.

Lorente Fernández L, Monte Boquet E, Pérez-Miralles F, Gil Gómez I, Escutia Roig M, Boscá Blasco I, Poveda Andrés JL, Casanova-Estruch B.

Neurologia. 2014 Jun;29(5):257-60. doi: 10.1016/j.nrl.2013.06.014. Epub 2013 Sep 10. English, Spanish.

2.

Clinical experience with THC:CBD oromucosal spray in patients with multiple sclerosis-related spasticity.

Koehler J, Feneberg W, Meier M, Pöllmann W.

Int J Neurosci. 2014 Sep;124(9):652-6. doi: 10.3109/00207454.2013.877460. Epub 2014 Jan 23.

PMID:
24392812
4.

Sativex for the management of multiple sclerosis symptoms.

Perras C.

Issues Emerg Health Technol. 2005 Sep;(72):1-4.

PMID:
16317825
5.

Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis.

Serpell MG, Notcutt W, Collin C.

J Neurol. 2013 Jan;260(1):285-95. doi: 10.1007/s00415-012-6634-z. Epub 2012 Aug 10.

PMID:
22878432
6.

Efficacy and safety of nabiximols (Sativex(®)) on multiple sclerosis spasticity in a real-life Italian monocentric study.

Ferrè L, Nuara A, Pavan G, Radaelli M, Moiola L, Rodegher M, Colombo B, Keller Sarmiento IJ, Martinelli V, Leocani L, Martinelli Boneschi F, Comi G, Esposito F.

Neurol Sci. 2016 Feb;37(2):235-42. doi: 10.1007/s10072-015-2392-x. Epub 2015 Oct 16.

PMID:
26474875
7.
8.
9.

Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis.

Collin C, Davies P, Mutiboko IK, Ratcliffe S; Sativex Spasticity in MS Study Group.

Eur J Neurol. 2007 Mar;14(3):290-6.

PMID:
17355549
10.
11.
12.

Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients.

Paolicelli D, Direnzo V, Manni A, D'Onghia M, Tortorella C, Zoccolella S, Di Lecce V, Iaffaldano A, Trojano M.

J Clin Pharmacol. 2016 Jul;56(7):845-51. doi: 10.1002/jcph.670. Epub 2015 Dec 30.

PMID:
26608223
13.

[There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis].

Bazinski H, Jensen HB, Stenager E.

Ugeskr Laeger. 2015 May 11;177(20):956-60. Review. Danish.

PMID:
26535431
14.

What is new in multiple sclerosis spasticity research? Poster session highlights.

Ghezzi A.

Neurodegener Dis Manag. 2016 Dec;6(6s):45-47.

PMID:
27874498
15.

A randomised controlled cross-over double-blind pilot study protocol on THC:CBD oromucosal spray efficacy as an add-on therapy for post-stroke spasticity.

Marinelli L, Balestrino M, Mori L, Puce L, Rosa GM, Giorello L, Currà A, Fattapposta F, Serrati C, Gandolfo C, Abbruzzese G, Trompetto C.

BMJ Open. 2017 Sep 7;7(9):e016843. doi: 10.1136/bmjopen-2017-016843.

16.

A cost-effectiveness model for the use of a cannabis-derived oromucosal spray for the treatment of spasticity in multiple sclerosis.

Gras A, Broughton J.

Expert Rev Pharmacoecon Outcomes Res. 2016 Dec;16(6):771-779. Epub 2016 Feb 26.

PMID:
26750641
17.

Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis.

Moreno Torres I, Sanchez AJ, Garcia-Merino A.

Expert Rev Neurother. 2014 Nov;14(11):1243-50. doi: 10.1586/14737175.2014.971758. Review.

PMID:
25331416
18.

Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis.

Syed YY, McKeage K, Scott LJ.

Drugs. 2014 Apr;74(5):563-78. doi: 10.1007/s40265-014-0197-5. Review.

PMID:
24671907
19.

Placebo effects in a multiple sclerosis spasticity enriched clinical trial with the oromucosal cannabinoid spray (THC/CBD): dimension and possible causes.

Di Marzo V, Centonze D.

CNS Neurosci Ther. 2015 Mar;21(3):215-21. doi: 10.1111/cns.12358. Epub 2014 Dec 4. Review.

PMID:
25475413
20.

[There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis].

Basinski H, Jensen HB, Stenager E.

Ugeskr Laeger. 2014 Mar 17;176(12A). pii: V09130552. Review. Danish.

PMID:
25350886

Supplemental Content

Support Center